Partnership and Disclosure
Disclosure-
Cellltrion Healthcare UK Ltd are committed to acting with openness and transparency across all our interactions with healthcare professionals (HCPs), other relavent decision makers (ORDMs) healthcare organisations (HCOs) patient organizations (POs) and members of the public to support patient care.
Our interactions are guided by transparency to ensure trust and confidence in the Pharmaceutical Industry and we support disclosure of these relationships to demonstrate their integrity. Cellltrion Healthcare UK Ltd are committed to working within the Association of the British Pharmaceutical Industry’s (ABPI) Code of Practice. To support this, our transparency disclosure of payments to HCPs; ORDMs: HCOs; POs and members of the public are published below.
Health Professionals, Other Relavent Decision Makers and Healthcare Organisations:
For transparency reports for HCPs, ORDMs and HCOs, see the Disclosure UK database hosted on the website of the ABPI, visit www.disclosureuk.org.uk.
Patient Organisations, Members of the Public and journalists:
Up until 2023 there has been no payment to patient orgnisations, members of public and journalist.
2023 - Information on payments made to support the work of patient organisations, Members of the Public (including patients and journalists). – please use this [link]
For information on our methodological approach please click here.
- Internal compliance
-
Celltrion Healthcare has ethics and compliance policies in a place that apply to all executives and employees.
We also seek to resolve possible conflicts between the company and its employees, the company and its partners, and the company and the authorities in an ethical and amicable manner , and fulfills to social responsibilities for compliance, transparency, fairness and ethical management.
Anyone can anonymously report or inform compliance concerns. All these concerns will be thoroughly investigated by the company's Chief Compliance Officer, while the identify of the informer will be strictly protected.
UK--23-00063 April 2024